Byron Hing Lung Lee MD PhD (He/Him)

Surgical Oncology

Associate Professor, Department of Urology, The University of Texas MD Anderson Cancer Center

Summary

Dr. Byron Lee, located in Houston, TX, is a urologist with a subspecialty in urologic oncology. Dr. Lee completed a medical degree and a Ph.D. in Cellular and Molecular Medicine at Johns Hopkins University, followed by a residency in urology at Cleveland Clinic Foundation and a fellowship in complex general surgical oncology at Memorial Sloan Kettering Cancer Center. Currently an associate professor at UT MD Anderson Cancer Center and a staff physician at Cleveland Clinic since 2016, Dr. Lee has extensive experience in prostate cancer, gynecologic oncology, urologic oncology, and bladder cancer. Dr. Lee has contributed to multiple publications in reputable journals and has received several certifications from Epic Systems Corporation. Dr. Lee was also recognized by Phi Beta Kappa and the Golden Key International Honour Society in 1998.

Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2014 - 2016
Cleveland Clinic FoundationResidency, Urology, 2007 - 2013
Johns Hopkins University School of MedicinePh.D., Cellular and Molecular Medicine, 2001 - 2007
Johns Hopkins University School of MedicineClass of 2007
Johns Hopkins UniversityB.A., Biology, General Honors, 1994 - 1998

CMS Meaningful Use Stage 1 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2017
CMS Meaningful Use Stage 1 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2017
CMS Meaningful Use Stage 1 Certification Sunquest Laboratory, Sunquest Information Systems, Inc., 2017

PubMed

Journal Articles

Robotic Partial Nephrectomy: Imperative vs Elective Indications
Long JA, Lee B, Eyraud R, Autorino R, Hillyer S, Stein RJ, Kaouk JH, Haber GP, Urology, 10/1/2012
Unique DNA Methylome Profiles in CpG Island Methylator Phenotype Colon Cancers
Xu Y, Hu B, Choi AJ, Gopalan B, Lee BH, Kalady MF, Church JM, Ting AH, Genome Res, 2/1/2012
Bilateral Synchronous Sporadic Renal Tumors: Pathologic Concordance and Clinical Implications
Patel AR, Lee BH, Campbell SC, Zhou M, Fergany AF, Urology, 11/1/2011

Books/Book Chapters

Imaging and Focal Therapy of Early Prostate Cancer
Chapter: Changing Landscape of Prostate Cancer Favoring Low Risk Prostate Cancer: Implications for Active Surveillance Versus Focal Therapy
Lee BH, Carroll PR, Klein EAEditors: Thomas Polascik.Springer Science and Business Media, New York, NY2012
Emerging Cancer Therapeutics
Chapter: Management of Small Renal Masses: Donating Kidneys to Your Local Pathologist is Not Advised
Campbell SC, Lee BHEditors: Walter Stadler.Demos Medical Publishing, New York2011

Abstracts/Posters

Are All High-grade Cancers Created Equally? An Analysis of Clinical and Features and Survival among Patients with Biopsy Gleason Score 8, 9, and 10 Disease
Lee BH, Garcia J, Dreicer R, Tendulkar R, Stephans K, Magi-Galluzzi C, Klein EA, Oh W, Stephenson AJ, American Urological Association 2012 Annual Meeting, Atlanta, GA, 1/1/2012
Regulatory Sequences of the ATP-Binding Cassette Transporter A1 (ABCA1) Gene Are Hypermethylated in Prostate Cancer Resulting in Loss of Gene Expression
Lee BH, Magi-Galluzzi C, Klein EA, Ting AH, American Urological Association 2011 Annual Meeting, Washington, DC, 1/1/2011
Comparison of Observed Prostate Cancer-specific Mortality by Treatment-specific, Nomogram-predicted Risks of Biochemical Recurrence in Men with Localized Prostate Canc...
Lee BH, Stephenson AJ, Ciezki JP, Klein EA, Reddy CA, Yu C, Kattan MW, Kibel AS, American Urological Association 2011 Annual Meeting, Washington, DC, 1/1/2011

AUA 2018 – Monday, May 21May 21st, 2018
Cleveland Clinic Physician Earns Two Prestigious Young Investigator AwardsAugust 7th, 2017
Attacking Bladder Cancer: Improving Efficiency, Clinical Management and ResearchNovember 23rd, 2017

High resolution transcriptome and gene regulatory mapping of human ureter and bladder across the lifespanCLEVELAND CLINIC LERNER COM-CWRU2021–2026
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder CancerUNIVERSITY OF TX MD ANDERSON CAN CTR2019–2025